Metabolomics to identify fingerprints of carotid atherosclerosis in nonobese metabolic dysfunction-associated fatty liver disease.
Congxiang ShaoLishu XuPingguang LeiWei WangShiting FengJunzhao YeBi-Hui ZhongPublished in: Journal of translational medicine (2023)
Diagnostic models combining different metabolites according to BMI categories could raise the accuracy of identifying subclinical CAS. Trial registration The study protocol was approved by the local ethics committee and all the participants have provided written informed consent (Approval number: [2014] No. 112, registered at the Chinese Clinical Trial Registry, ChiCTR-ChiCTR2000034197).
Keyphrases
- study protocol
- clinical trial
- drug administration
- randomized controlled trial
- crispr cas
- phase ii
- genome editing
- phase iii
- open label
- ms ms
- mass spectrometry
- public health
- body mass index
- cardiovascular disease
- double blind
- oxidative stress
- big data
- weight gain
- placebo controlled
- fatty acid
- global health
- machine learning
- type diabetes
- artificial intelligence